A Phase 1 interventional study of MK-8226 and Placebo in Atopic Dermatitis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis. Part 1 (multiple rising dose study) objectives were to find the maximum tolerated dose (MTD) of MK-8226 and to assess safety and PK. Part 2 objectives were to determine safety, PK, and preliminary efficacy. Part 3 objectives were to further define safety and PK, and explore MK-8226 PK/PD to model the optimal dose range for future studies. The study was terminated early due to business reasons on 08 May 2014; final results from an analysis for Part 1 (efficacy, PK, safety, immunogenicity) and Part 2 (safety, immunogenicity) are summarized.
Part 1 of the study is a multiple rising dose assessment of the safety, tolerability, and pharmacokinetics of MK-8226 for a period of 12 weeks followed by a 20-week off-treatment follow-up period.
Part 2 of the study is an assessment of the safety, tolerability, and efficacy of MK-8226 for 12 weeks followed by a 20-week off-treatment follow-up period.
In Part 3 of the study, participants will be treated with MK-8226 for a period of 12 weeks followed by a 20-week off-treatment follow-up period to evaluate pharmacokinetic and pharmacokinetic correlations to assist with modeling the dose range planned for further studies.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
This study's enrollment of 65 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
Drug: MK-8226
MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
Drug: MK-8226
MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
Drug: MK-8226
MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
Drug: MK-8226
Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
Drug: Placebo
MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
Drug: MK-8226
Placebo administered IV every 2 weeks for a period of 12 weeks.
Drug: Placebo
MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
Placebo administered IV every 2 weeks for a period of 12 weeks.
Number of Participants Who Experienced at Least One Adverse Event
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 32 Weeks
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
Time frame: Up to 12 Weeks
Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1
Reduction from baseline in EASI at Week 12 (interim analysis data). The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
Time frame: Baseline, Week 12
Plasma Chemokine (C-C Motif) Ligand 17 (CCL17) Level in Study Part 2
CCL17 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL17 are increased in allergic disease states.
Time frame: Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16
Plasma Chemokine (C-C Motif) Ligand 22 (CCL22) Level in Study Part 2
CCL22 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL22 are increased in allergic disease states.
Time frame: Baseline, 48 Hours, Week 2, Week 4, Week 12, Week 16
Area Under the Concentration-time Curve of MK-8226 From Time 0 to Tau (AUC0-tau) Following Multiple Intravenous Dose Administration
AUC(0-tau) defined as AUC from time zero to tau where tau is the dosing interval (312 hours) was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 1, 3, 5, 9, 14, 70, 72, 74, 84
AUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration
AUC0-last defined as AUC up to the last measured concentration was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Maximum Serum Concentration (Cmax) of MK-8226 Following Multiple Dose Intravenous Administration
Cmax was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 1, 3, 5, 9, 14, 70, 72, 74, 84
Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration
CL, the volume of plasma cleared of drug per unit time, was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 28 (incl. predose), 42 (incl. predose), 56 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 1, 3, 5, 9, 14, 28, 42, 56, 70, 72, 74, 84
Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration
Vd, a theoretical approximation of degree to which the drug distributes in body tissue rather than plasma (higher Vd indicates greater tissue distribution), was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Terminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration
t1/2, the time needed for the concentration of drug to reach half the initial concentration, was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
Time frame: Days 70, 72, 74, 84, 98, 112, 140, 168, 196, 224
Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 2
The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
Time frame: Baseline, Week 4, Week 8, Week 24
Percentage of Participants With an Investigator Global Assessment (IGA) Score of Clear or Almost Clear in Study Part 2
Percentage of participants achieving an IGA of atopic dermatitis of "clear-0" or "almost clear-1". The IGA is a six-point scale measuring the severity of disease at time of physical examination of the participant by the physician. The IGA is scored 0 (Clear) to 5 (Very severe disease).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24
Change From Baseline in the Scoring Atopic Dermatitis Scale (SCORAD) in Study Part 2
The SCORAD index scale combines 1) intensity of six lesion characteristics (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness) as assessed by the physician on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities) along with 2) subjective symptoms of pruritus and sleep disturbance as reported by the patient on a visual analog scale (VAS) from 1 to 10 cm (increasing severity). Physician assessment of affected areas in each region is made as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The final SCORAD index score, ranging from 0 (absent disease) to 103 (severe disease), is calculated according to the weighted formula: (0.2 x area) + (3.5 x \[sum of intensity score for each of the 6 items\]) + participant's subjective score.
Time frame: Baseline, Week 4, Week 12, Week 24
Change From Baseline in Participant Pruritus in Study Part 2
Skin pruritus (itching) is a typical characteristic of atopic dermatitis. Participant subjective assessment of pruritus (component of SCORAD) is rated on a VAS ranging from 1 to 10 cm (increasing severity).
Time frame: Baseline, Week 4, Week 12, Week 24
Change From Baseline in Participant Sleep Disturbance in Study Part 2
Sleep disturbance (sleep loss, disruption, or interference) due to unremitting pruritus and other causes is a quality of life issue in moderate to severe atopic dermatitis. Participant subjective assessment of sleep disturbance (component of SCORAD) over the past 3 days is rated on a VAS ranging from 1 to 10 cm (increasing severity).
Time frame: Baseline, Week 4, Week 12, Week 24
Number of Participants Requiring As-Needed Oral Antihistamines as Rescue Medication in Study Part 2
Oral antihistamines (i.e., diphenhydramine, acrivastine fenistil) were provided as as-needed rescue medication for severe pruritus.
Time frame: Up to Week 12
Percentage of Participants With >=50% Improvement in EASI Score
The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
Time frame: Baseline, Week 12, Week 24
Number of Participants Positive for Anti-Drug Antibody (ADA) Formation
Testing for ADA positivity and neutralizing response and antibody titre quantification are performed with blood (serum) samples collected at baseline (Day 1 predose) and Days 14, 28, 42, 56, 74, 112, and 224. Neutralizing response refers to ADA neutralizing interference with study drug assessed in vitro. Non-Treatment emergent ADA refers to presence of ADAs (as determined by assay) in the absence of treatment with study drug (i.e., at predose).
Time frame: Days 1 (predose) and Days 14, 28, 42, 56, 74, 112, and 224
Change From Baseline in the Participant's Global Impression of Disease Status in Study Part 2
Participant subjective impression of improvement of his/her disease condition is scored on a six-point scale: 0 (Clear) to 5 (Very severe disease).
Time frame: Baseline, Week 4, Week 12, Week 24
| Milestone | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| Started | 9 | 9 | 8 | 10 | 8 | 13 | 8 |
| Completed | 8 | 4 | 4 | 5 | 3 | 0 | 0 |
| Not completed | 1 | 5 | 4 | 5 | 5 | 13 | 8 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 | 1 | 5 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 1 | 0 | 12 | 6 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| participants | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event | 8 | 6 | 6 | 7 | 7 | 10 | 7 |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
| participants | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Reduction from baseline in EASI at Week 12 (interim analysis data). The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
| Score on a scale | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) |
|---|---|---|---|---|---|
| Change From Baseline in the Eczema Area and Severity Index (EASI) for Study Part 1 | -5.77 ± 6.17 | -8.40 ± 9.39 | -10.20 ± 7.23 | -7.78 ± 8.35 | -0.38 ± 6.37 |
CCL17 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL17 are increased in allergic disease states.
No measurements were reported for this outcome.
CCL22 is a pro-allergic chemokine that is assessed in human plasma. Levels of CCL22 are increased in allergic disease states.
No measurements were reported for this outcome.
AUC(0-tau) defined as AUC from time zero to tau where tau is the dosing interval (312 hours) was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| μg*hr/mL | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| Week 1 (n=9,7,8,10) | 1000 ± 18.2 | 3300 ± 29.3 | 9300 ± 19.1 | 31400 ± 11.2 |
| Week 10 (n=8,5,6,6) | 2310 ± 11 | 8530 ± 15.4 | 21100 ± 28.8 | 82100 ± 16.2 |
AUC0-last defined as AUC up to the last measured concentration was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| μg*hr/mL | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| AUC From Time 0 to Last Measurement (AUC0-last) of MK-8226 Following Multiple Intravenous Dose Administration | 6460 ± 34.3 | 22600 ± 65.8 | 47100 ± 97.2 | 264000 ± 25.2 |
Cmax was determined for the first and last periods of MK-8226 dosing. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| μg/mL | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| Week 1 (n=9,8,8,10) | 7.12 ± 21.9 | 21.6 ± 26.0 | 60.3 ± 18.0 | 200 ± 12.1 |
| Week 10 (n=8,6,6,6) | 11.7 ± 9.63 | 42.4 ± 20.1 | 106 ± 19.6 | 398 ± 17.1 |
CL, the volume of plasma cleared of drug per unit time, was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 1 (incl. predose), 3, 5, 9, 14 (incl. predose), 28 (incl. predose), 42 (incl. predose), 56 (incl. predose), 70 (incl. predose), 72, 74, and 84. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| mL/day/kg | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| Clearance (CL) of MK-8226 Following Multiple Dose Intravenous Administration | 3.04 ± 11 | 2.81 ± 15.4 | 3.33 ± 28.8 | 2.9 ± 16.2 |
Vd, a theoretical approximation of degree to which the drug distributes in body tissue rather than plasma (higher Vd indicates greater tissue distribution), was determined for the last period of dosing (starting Week 10 \[Day 70\]) in the treatment period. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| mL/kg | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| Volume of Distribution (Vd) of MK-8226 Following Multiple Intravenous Administration | 103 ± 27.6 | 122 ± 26.8 | 102 ± 62.1 | 120 ± 25.3 |
t1/2, the time needed for the concentration of drug to reach half the initial concentration, was determined for the last period of dosing (starting Week 10 \[Day 70\]) up to the last measurement. MK-8226 was administered on Days 1, 14, 28, 42, 56, and 70. Blood concentrations of MK-8226 were determined on Days 70 (incl. predose), 72, 74, 84, 98, 112, 140, 168, 196, and 224. The placebo group is not included; this endpoint evaluated only the MK-8226 groups. No analysis was performed for Part 2 non-safety secondary endpoints after the Part 1 primary endpoint (Change from BL in EASI) did not demonstrate adequate effect in an interim futility analysis.
| days | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg |
|---|---|---|---|---|
| Terminal Half Life (t1/2) of MK-8226 Following Multiple Dose Intravenous Administration | 23.6 ± 33.5 | 30 ± 15.9 | 24.7 ± 51.3 | 28.7 ± 15.7 |
The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
No measurements were reported for this outcome.
Percentage of participants achieving an IGA of atopic dermatitis of "clear-0" or "almost clear-1". The IGA is a six-point scale measuring the severity of disease at time of physical examination of the participant by the physician. The IGA is scored 0 (Clear) to 5 (Very severe disease).
No measurements were reported for this outcome.
The SCORAD index scale combines 1) intensity of six lesion characteristics (erythema, edema/papulation, oozing/crusts, excoriations, lichenification, dryness) as assessed by the physician on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities) along with 2) subjective symptoms of pruritus and sleep disturbance as reported by the patient on a visual analog scale (VAS) from 1 to 10 cm (increasing severity). Physician assessment of affected areas in each region is made as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The final SCORAD index score, ranging from 0 (absent disease) to 103 (severe disease), is calculated according to the weighted formula: (0.2 x area) + (3.5 x \[sum of intensity score for each of the 6 items\]) + participant's subjective score.
No measurements were reported for this outcome.
Skin pruritus (itching) is a typical characteristic of atopic dermatitis. Participant subjective assessment of pruritus (component of SCORAD) is rated on a VAS ranging from 1 to 10 cm (increasing severity).
No measurements were reported for this outcome.
Sleep disturbance (sleep loss, disruption, or interference) due to unremitting pruritus and other causes is a quality of life issue in moderate to severe atopic dermatitis. Participant subjective assessment of sleep disturbance (component of SCORAD) over the past 3 days is rated on a VAS ranging from 1 to 10 cm (increasing severity).
No measurements were reported for this outcome.
Oral antihistamines (i.e., diphenhydramine, acrivastine fenistil) were provided as as-needed rescue medication for severe pruritus.
No measurements were reported for this outcome.
Participant subjective impression of improvement of his/her disease condition is scored on a six-point scale: 0 (Clear) to 5 (Very severe disease).
No measurements were reported for this outcome.
The EASI assesses intensity of four lesion characteristics (erythema, infiltration/population, excoriation, lichenification) each rated on a scale of 0 (absent) to 3 (severe) across four regions (head, trunk, upper and lower extremities). Affected areas in each region are assessed as percentage of body surface (head \[10%\], trunk \[30%\], upper extremities \[20%\], and lower extremities \[40%\]). The total score is a sum of each region score and can range from 0 (absent disease) to 72 (severe disease).
No measurements were reported for this outcome.
Testing for ADA positivity and neutralizing response and antibody titre quantification are performed with blood (serum) samples collected at baseline (Day 1 predose) and Days 14, 28, 42, 56, 74, 112, and 224. Neutralizing response refers to ADA neutralizing interference with study drug assessed in vitro. Non-Treatment emergent ADA refers to presence of ADAs (as determined by assay) in the absence of treatment with study drug (i.e., at predose).
| Participants | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| Non Treatment emergent ADA positive | 0 | 1 | 0 | 0 | — | 0 | 0 |
| Treatment emergent ADA positive | 0 | 0 | 1 | 0 | — | 2 | 0 |
| ADA positive: Max titer 1:10 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| ADA positive: Max titer 1:50 | 0 | 0 | 1 | 0 | — | 1 | 0 |
| ADA positive: Neutralizing response positive | 0 | 0 | 1 | 0 | — | 1 | 0 |
Collected over Up to 32 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: MK-8226 0.3 mg/kg | — | 0/9 (0%) | 8/9 (88.9%) |
| Part 1: MK-8226 1 mg/kg | — | 0/9 (0%) | 6/9 (66.7%) |
| Part 1: MK-8226 3 mg/kg | — | 0/8 (0%) | 6/8 (75%) |
| Part 1: MK-8226 10 mg/kg | — | 1/10 (10%) | 7/10 (70%) |
| Part 1: Placebo (Pooled) | — | 0/8 (0%) | 7/8 (87.5%) |
| Part 2: MK-8226 3 mg/kg | — | 0/13 (0%) | 10/13 (76.9%) |
| Part 2: Placebo | — | 1/8 (12.5%) | 7/8 (87.5%) |
| Event | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| ErysipelasInfections and infestations | 0/9 | 0/9 | 0/8 | 0/10 | 0/8 | 0/13 | 1/8 |
| Abortion inducedSurgical and medical procedures | 0/9 | 0/9 | 0/8 | 1/10 | 0/8 | 0/13 | 0/8 |
| Event | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/9 | 1/9 | 1/8 | 3/10 | 2/8 | 4/13 | 2/8 |
| Skin infectionInfections and infestations | 0/9 | 0/9 | 2/8 | 0/10 | 0/8 | 0/13 | 0/8 |
| Urinary tract infectionInfections and infestations | 0/9 | 0/9 | 0/8 | 0/10 | 0/8 | 0/13 | 2/8 |
| HeadacheNervous system disorders | 2/9 | 0/9 | 1/8 | 1/10 | 1/8 | 3/13 | 2/8 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/9 | 1/9 | 1/8 | 1/10 | 0/8 | 3/13 | 1/8 |
| Abdominal painGastrointestinal disorders | 0/9 | 0/9 | 1/8 | 0/10 | 0/8 | 0/13 | 0/8 |
| FatigueGeneral disorders | 1/9 | 1/9 | 1/8 | 0/10 | 0/8 | 0/13 | 0/8 |
| Gravitational oedemaGeneral disorders | 0/9 | 0/9 | 0/8 | 0/10 | 1/8 | 0/13 | 0/8 |
| Peripheral swellingGeneral disorders | 0/9 | 0/9 | 0/8 | 0/10 | 1/8 | 0/13 | 0/8 |
| BronchitisInfections and infestations | 1/9 | 1/9 | 0/8 | 0/10 | 0/8 | 0/13 | 1/8 |
| Age, Categorical(Participants) | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 9 | 8 | 10 | 8 | 13 | 8 | 64 |
| >=65 years | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Age, Continuous(years) | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 49.0 ± 11.8 | 30.8 ± 13.4 | 41.6 ± 12.6 | 34.7 ± 10.2 | 37.8 ± 14.2 | 38.3 ± 11.5 | 33.9 ± 12.9 | 38.0 ± 12.9 |
| Sex: Female, Male(Participants) | Part 1: MK-8226 0.3 mg/kg | Part 1: MK-8226 1 mg/kg | Part 1: MK-8226 3 mg/kg | Part 1: MK-8226 10 mg/kg | Part 1: Placebo (Pooled) | Part 2: MK-8226 3 mg/kg | Part 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 4 | 6 | 5 | 8 | 3 | 32 |
| Male | 5 | 7 | 4 | 4 | 3 | 5 | 5 | 33 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
No publications or documents are linked to this record.
Ran from Dec 2012 to primary completion in Oct 2014, 21 months.
Results were first posted in Jun 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solrikitug